These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29679282)

  • 1. Burosumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Apr; 78(6):707-714. PubMed ID: 29679282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
    Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
    Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
    Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of X-linked hypophosphataemia.
    Imel EA; White KE
    Br J Clin Pharmacol; 2019 Jun; 85(6):1188-1198. PubMed ID: 30207609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
    Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
    Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
    Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
    J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
    Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
    J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
    Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
    Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
    Portale AA; Carpenter TO; Brandi ML; Briot K; Cheong HI; Cohen-Solal M; Crowley R; Jan De Beur S; Eastell R; Imanishi Y; Imel EA; Ing S; Ito N; Javaid M; Kamenicky P; Keen R; Kubota T; Lachmann R; Perwad F; Pitukcheewanont P; Ralston SH; Takeuchi Y; Tanaka H; Weber TJ; Yoo HW; Zhang L; Theodore-Oklota C; Mealiffe M; San Martin J; Insogna K
    Calcif Tissue Int; 2019 Sep; 105(3):271-284. PubMed ID: 31165191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.
    Insogna KL; Rauch F; Kamenický P; Ito N; Kubota T; Nakamura A; Zhang L; Mealiffe M; San Martin J; Portale AA
    J Bone Miner Res; 2019 Dec; 34(12):2183-2191. PubMed ID: 31369697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
    Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
    Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
    Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.